Co-Diagnostics, Inc. (LON:0A50)

Market Cap	3.89M -80.7%
Revenue (ttm)	377.84K -93.1%
Net Income	-23.94M
EPS	-21.58
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	96
Average Volume	2,844
Open	2.290
Previous Close	2.400
Day's Range	2.290 - 2.290
52-Week Range	2.200 - 46.173
Beta	1.26
RSI	26.59
Earnings Date	Mar 19, 2026

About Co-Diagnostics

Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 2013
• Employees: 132
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0A50

Financial Performance

In 2024, Co-Diagnostics's revenue was $3.92 million, a decrease of -42.53% compared to the previous year's $6.81 million. Losses were -$37.64 million, 6.53% more than in 2023.

Financial numbers in USD